 |
31 Diseases |  |
34 Trials |
|
34 Trials |  |
1690 News |  |
| «12...78910111213141516171819» |
- ||||||| linagliptin / Generic mfg.
Trial completion, Combination therapy: Linagliptin Add-on to Insulin Background Therapy (clinicaltrials.gov) - Jan 29, 2019
P3, N=206, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed
- |||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
New trial, Real-world evidence, Real-world: DIA_CENTRAL:T2D Treatment Pattern in Central Europe (clinicaltrials.gov) - Jan 17, 2019
P, N=4000, Not yet recruiting, Sponsor: Boehringer Ingelheim
- | Trial primary completion date, Bariatric surgery: Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment (clinicaltrials.gov) - Dec 11, 2018
P4, N=40, Recruiting, Sponsor: Khoo Teck Puat Hospital
Active, not recruiting --> Completed Trial primary completion date: Mar 2018 --> Mar 2020
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P3 trial: Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus. (clinicaltrials.gov) - Dec 6, 2018
P3, N=480, Not yet recruiting, Sponsor: EMS
- ||| linagliptin / Generic mfg.
Trial completion: PMS of Trazenta on the Long-term Use as Add-on Therapy (clinicaltrials.gov) - Oct 9, 2018
P=N/A, N=4058, Completed, Sponsor: Boehringer Ingelheim
Trial primary completion date: Mar 2018 --> Mar 2020 Active, not recruiting --> Completed
- || linagliptin / Generic mfg.
Trial completion date, Trial primary completion date: Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin (clinicaltrials.gov) - Oct 9, 2018
P=N/A, N=99999, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Aug 2018 --> Nov 2018
- ||||| linagliptin / Generic mfg.
Enrollment closed, Combination therapy: Linagliptin Add-on to Insulin Background Therapy (clinicaltrials.gov) - Sep 21, 2018
P3, N=206, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Aug 2018 --> Nov 2018 Recruiting --> Active, not recruiting
- | Sulonex (sulodexide) / Alfasigma, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment change, Trial withdrawal: Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2) (clinicaltrials.gov) - Sep 14, 2018
P4, N=0, Withdrawn, Sponsor: Steno Diabetes Center
Recruiting --> Active, not recruiting N=20 --> 0 | Recruiting --> Withdrawn
- | NN1213 / Novo Nordisk
Trial primary completion date: CANDY-CANE: Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management (clinicaltrials.gov) - Sep 13, 2018
P=N/A, N=3, Completed, Sponsor: University of Washington
N=20 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Aug 2018 --> Aug 2017
- |||| linagliptin / Generic mfg.
Trial completion date, Trial primary completion date: CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes (clinicaltrials.gov) - Sep 4, 2018
P3, N=6103, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Aug 2018 --> Aug 2017 Trial completion date: Mar 2019 --> Aug 2018 | Trial primary completion date: Feb 2019 --> Aug 2018
- | Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
New trial: A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease (clinicaltrials.gov) - Aug 27, 2018
P=N/A, N=714582, Completed, Sponsor: Janssen Research & Development, LLC
- | Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
Trial completion: A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease (clinicaltrials.gov) - Aug 27, 2018
P=N/A, N=714582, Completed, Sponsor: Janssen Research & Development, LLC
Trial completion date: Mar 2019 --> Aug 2018 | Trial primary completion date: Feb 2019 --> Aug 2018 Recruiting --> Completed
- | linagliptin / Generic mfg.
Trial termination: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Aug 16, 2018
P1, N=1, Terminated, Sponsor: Monash University
Recruiting --> Completed Suspended --> Terminated; Inability to obtain patients
- | linagliptin / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: DYDA2: Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry (clinicaltrials.gov) - Aug 9, 2018
P3, N=188, Active, not recruiting, Sponsor: Heart Care Foundation
Suspended --> Terminated; Inability to obtain patients Recruiting --> Active, not recruiting | Trial completion date: May 2018 --> Apr 2019 | Trial primary completion date: May 2018 --> Apr 2019
- || NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: CANDY-CANE: Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management (clinicaltrials.gov) - Aug 8, 2018
P=N/A, N=3, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting | Trial completion date: May 2018 --> Apr 2019 | Trial primary completion date: May 2018 --> Apr 2019 Recruiting --> Completed | N=24 --> 3 | Trial completion date: Dec 2019 --> Aug 2018 | Trial primary completion date: Dec 2018 --> Aug 2018
- linagliptin / Generic mfg.
Trial completion date, Trial primary completion date: Linagliptin's Effect on CD34+ Stem Cells (clinicaltrials.gov) - Aug 7, 2018
P4, N=40, Recruiting, Sponsor: George Washington University
Recruiting --> Completed | N=24 --> 3 | Trial completion date: Dec 2019 --> Aug 2018 | Trial primary completion date: Dec 2018 --> Aug 2018 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Apr 2018 --> Apr 2019
- | Kanarb (fimasartan) - Boryung Group, R / Pharm
New P1 trial: A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers (clinicaltrials.gov) - Aug 1, 2018
P1, N=60, Recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion date, Trial primary completion date: VCG4: Contrast Nephropathy in Type 2 Diabetes (clinicaltrials.gov) - Jul 31, 2018
P=N/A, N=40, Recruiting, Sponsor: Ahmed Abdelkawi Hammad
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Apr 2018 --> Apr 2019 Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Sep 2018
- | Sugarnon (evogliptin) - Dong / A
Trial completion, Trial completion date: Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN) (clinicaltrials.gov) - Jul 23, 2018
P4, N=207, Completed, Sponsor: Dong-A ST Co., Ltd.
Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Sep 2018 Recruiting --> Completed | Trial completion date: Dec 2018 --> Mar 2018
- || linagliptin / Generic mfg.
Trial completion date, Trial primary completion date: Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin (clinicaltrials.gov) - Jul 10, 2018
P=N/A, N=99999, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | Trial completion date: Dec 2018 --> Mar 2018 Trial completion date: May 2018 --> Aug 2018 | Trial primary completion date: May 2018 --> Aug 2018
- ||| Tenelia (teneligliptin) / Daiichi Sankyo, Mitsubishi Tanabe
Enrollment open, Trial completion date, Trial primary completion date, Head-to-Head: TELIUS: Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients (clinicaltrials.gov) - Jun 8, 2018
P4, N=164, Recruiting, Sponsor: Handok Pharmaceuticals Co., Ltd.
Trial completion date: May 2018 --> Aug 2018 | Trial primary completion date: May 2018 --> Aug 2018 Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Apr 2019 | Trial primary completion date: Aug 2018 --> Jan 2019
- | Sulonex (sulodexide) / Alfasigma, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2) (clinicaltrials.gov) - Apr 19, 2018
P4, N=20, Recruiting, Sponsor: Steno Diabetes Center
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Enrollment change: DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure (clinicaltrials.gov) - Mar 22, 2018
P4, N=10, Completed, Sponsor: Mitsui Memorial Hospital
Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Apr 2019 | Trial primary completion date: Aug 2018 --> Jan 2019 Recruiting --> Completed | N=50 --> 10
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New trial: VCG4: Contrast Nephropathy in Type 2 Diabetes (clinicaltrials.gov) - Mar 20, 2018
P=N/A, N=40, Recruiting, Sponsor: Ahmed Abdelkawi Hammad
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice. (Pubmed Central) - Mar 1, 2018
Recruiting --> Completed | N=50 --> 10 Together, these in vivo and in vitro results suggest that inhibition of DPP-4 activity by linagliptin reverses WD-induced DD, possibly by targeting TRAF3IP2 expression and its downstream inflammatory signaling.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion date, Trial primary completion date: DYDA2: Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry (clinicaltrials.gov) - Feb 22, 2018
P3, N=186, Recruiting, Sponsor: Heart Care Foundation
Together, these in vivo and in vitro results suggest that inhibition of DPP-4 activity by linagliptin reverses WD-induced DD, possibly by targeting TRAF3IP2 expression and its downstream inflammatory signaling. Trial primary completion date: Dec 2017 --> May 2018 | Trial completion date: Dec 2017 --> May 2018
- |||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Trial completion date: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) (clinicaltrials.gov) - Feb 12, 2018
P4, N=7003, Completed, Sponsor: Boehringer Ingelheim
Trial primary completion date: Dec 2017 --> May 2018 | Trial completion date: Dec 2017 --> May 2018 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Real-world evidence, Real-world: Real World Glycemic Effectiveness of Linagliptin (clinicaltrials.gov) - Feb 12, 2018
P=N/A, N=13962, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 Active, not recruiting --> Completed
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Byetta (exenatide) / AstraZeneca
Trial completion, Enrollment change: SAFEGUARD: Safety Evaluation of Adverse Reactions in Diabetes (clinicaltrials.gov) - Feb 7, 2018
P4, N=42, Completed, Sponsor: Charles University, Czech Republic
Active, not recruiting --> Completed Recruiting --> Completed | N=60 --> 42
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed, Real-world evidence, Real-world: Real World Glycemic Effectiveness of Linagliptin (clinicaltrials.gov) - Jan 19, 2018
P=N/A, N=13962, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | N=60 --> 42 Not yet recruiting --> Active, not recruiting
- | Kanarb (fimasartan) - Boryung Group, R / Pharm
Trial completion: A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers (clinicaltrials.gov) - Jan 18, 2018
P1, N=39, Completed, Sponsor: Boryung Pharmaceutical Co., Ltd
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date, Combination therapy: Linagliptin Add-on to Insulin Background Therapy (clinicaltrials.gov) - Dec 26, 2017
P3, N=206, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed Trial primary completion date: Aug 2018 --> Nov 2018
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed, Trial primary completion date: Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin (clinicaltrials.gov) - Nov 29, 2017
P=N/A, N=99999, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Aug 2018 --> Nov 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> May 2018
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones (clinicaltrials.gov) - Nov 29, 2017
P4, N=12, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> May 2018 Not yet recruiting --> Completed
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Nov 17, 2017
P=N/A, N=2877, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Completed Active, not recruiting --> Completed
- |||| Enrollment open: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Nov 17, 2017
P1/2, N=307, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: PMS of Trazenta on the Long-term Use as Add-on Therapy (clinicaltrials.gov) - Nov 13, 2017
P=N/A, N=4058, Active, not recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2018 --> Sep 2018
- ||||| New P1/2 trial: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Nov 9, 2017
P1/2, N=307, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New trial, Real-world evidence, Real-world: Real World Glycemic Effectiveness of Linagliptin (clinicaltrials.gov) - Nov 9, 2017
P=N/A, N=13962, Not yet recruiting, Sponsor: Boehringer Ingelheim
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed, Trial primary completion date: The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects (clinicaltrials.gov) - Nov 6, 2017
P4, N=40, Active, not recruiting, Sponsor: University at Buffalo
Trial primary completion date: Jun 2018 --> Sep 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Feb 2018
- |||| Zafatek (trelagliptin) / Takeda
Trial completion: Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Oct 31, 2017
P4, N=219, Completed, Sponsor: Takeda
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Feb 2018 Active, not recruiting --> Completed
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: Long-term Daily Use of Trazenta (clinicaltrials.gov) - Oct 27, 2017
P=N/A, N=4554, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed, Enrollment change: PRELLIM: Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes (clinicaltrials.gov) - Oct 27, 2017
P4, N=139, Active, not recruiting, Sponsor: Universidad de Guanajuato
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=75 --> 139
- |||| Cotellic (cobimetinib) / Exelixis, Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, Metastases: MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - Oct 24, 2017
P1/2, N=357, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=75 --> 139 Not yet recruiting --> Recruiting
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P4 trial: A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy (clinicaltrials.gov) - Oct 24, 2017
P4, N=232, Recruiting, Sponsor: Yanbing Li
- ||||| Cotellic (cobimetinib) / Exelixis, Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
New P1/2 trial, Metastases: MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - Sep 13, 2017
P1/2, N=357, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial initiation date, Trial primary completion date: Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department (clinicaltrials.gov) - Sep 11, 2017
P3, N=60, Not yet recruiting, Sponsor: Rabin Medical Center
Not yet recruiting --> Recruiting Initiation date: Feb 2017 --> Oct 2017 | Trial primary completion date: Jul 2018 --> Nov 2018
- Kanarb (fimasartan) - Boryung Group, R / Pharm
Enrollment open: A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers (clinicaltrials.gov) - Aug 31, 2017
P1, N=37, Recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
Initiation date: Feb 2017 --> Oct 2017 | Trial primary completion date: Jul 2018 --> Nov 2018 Active, not recruiting --> Recruiting
- | Bariatric surgery: Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment (clinicaltrials.gov) - Aug 22, 2017
P4, N=40, Recruiting, Sponsor: Khoo Teck Puat Hospital
Active, not recruiting --> Recruiting Trial primary completion date: Mar 2017 --> Mar 2018
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed: A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 17, 2017
P=N/A, N=3000, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Mar 2017 --> Mar 2018 Recruiting --> Active, not recruiting